



Deadline	<b>Tue 18 Feb 2020 2 PM CET Pre-proposals (IOCB deadline Fri 14 Feb 2020)</b> <b>Tue 16 Jun 2020 2 PM CEST Full-proposals (IOCB deadline Fri 12 Jun 2020)</b>
Call name	2st Joint Call for European Joint Programme on Rare Diseases: <b>Pre-clinical Research to Develop Effective Therapies for Rare Diseases</b>
www	EJP RD: <a href="http://www.ejprarediseases.org/index.php/funding/">http://www.ejprarediseases.org/index.php/funding/</a> <a href="http://www.ejprarediseases.org/index.php/open-call-jtc2020/">http://www.ejprarediseases.org/index.php/open-call-jtc2020/</a> MEYS: : <a href="http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-v-oblasti-vzacnych-onemocneni-v-ramci-e-rare-1">http://www.msmt.cz/vyzkum-a-vyvoj-2/iniciativa-v-oblasti-vzacnych-onemocneni-v-ramci-e-rare-1</a>
Focused on	Fundamental, translation research
PI	Consortium of 4–6 (8 when from the underrepresented countries) partners (senior researchers, junior researchers, postdocs) represented by a coordinator
Eligible organisation	Research organisations / public higher education institutions / clinical/public health sector /participation of SMEs is encouraged; national/regional regulations may apply. Participating country: Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Luxembourg, Netherlands, Poland, Portugal, Slovakia, Spain, Sweden, Switzerland and Turkey.
Target group	Multinational research groups collaboration: Consortium 4-6 partners from at least. 4 countries, with participation of underrepresented countries up to 8 partners, max. 2 partners from the same country in 1 consortium
Expected outputs	Not specified
Call opens	Wed 18 Dec 2019
IOCB deadline	<b>Fri 14 Feb 2020 Pre-proposals</b> <b>Fri 12 Jun 2020 Full-proposals</b>
Final deadline	<ul style="list-style-type: none"> <li><b>Tue 18 Feb 2020 17:00 CET Pre-proposals</b> One joint proposal per consortium- submission website: <a href="https://ptoutline.eu/app/ejprd20">https://ptoutline.eu/app/ejprd20</a> Czech participant: MEYS: both by electronic correspondence to <a href="mailto:judita.klosakova@msmt.cz">judita.klosakova@msmt.cz</a> and post (one signed and stamped hard copy)</li> <li><b>Tue 16 Jun 2020 17:00 CET Full-proposals</b> - same as pre-proposals</li> </ul>
Evaluation results	Results of Pre-proposals assessment: end of Apr 2020 Rebuttal stage: 22-28 July 2020 Results of Full-proposals assessment: Nov 2020
Signature of agreement	
Earliest date of implementation	The first half of 2021 (common project start date)
Latest date of implementation	
Sustainability	none
Reporting	Joint brief annual scientific project reports (28 Feb 2022 and subsequent years) and final scientific project report within 6 months of the end of the project); intermediate and final status symposiums for Czech participants – MEYS, annual scientific and financial reports due 31 January of the following years);
Project duration (min-max)	<b>up to 36 months</b>
Allocation for the call	Total 24,65 M EUR, MEYS 0.6 M EUR
Project budget (min-max)	No restriction; max. 2-3 Czech research groups will be funded
Success rate	10 % (in 2019)
Eligible costs	Czech participant: §2 of the Act. No 130/2002 Coll. direct costs: personnel, consumables, equipment, travel, other costs indirect costs: overheads max 25% (fat rate) of direct costs without subcontracting Only the research and knowledge-dissemination organizations are eligible for the MEYS support.

Reimbursement	100 %
Mode of funding	ex-ante
Language of application	English/Czech for MEYS
Provider	<p>Consortium of 30 funding bodies from 22 countries (for Czech participants – MEYS) Ministry of Education, Youth and Sports of the Czech Republic (MEYS); <a href="http://www.msmt.cz">www.msmt.cz</a>  Ms. Judita Klosakova; <a href="mailto:judita.klosakova@msmt.cz">judita.klosakova@msmt.cz</a> , +420 234 811 504  <b>Joint Call Secretariat</b> at ANR (FR): <a href="http://www.ejprarediseases.org">www.ejprarediseases.org</a>; <a href="mailto:EJPRDcall@anr.fr">EJPRDcall@anr.fr</a>  Florence Guillot; <a href="mailto:florence.guillot@agencerecherche.fr">florence.guillot@agencerecherche.fr</a>; +33 (0) 1 78 09 80 01  Kiri Couchman; <a href="mailto:kiri.couchman@agencerecherche.fr">kiri.couchman@agencerecherche.fr</a>; +33 (0) 1 78 09 81 29</p>
Call identifier	EJ PRD JTC 2020
Call info	The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear future benefit for patients with rare diseases.
Conditions / Restrictions	<ul style="list-style-type: none"> <li>• Project shall involve a group of rare diseases or a single rare disease following the European definition i.e. a disease affecting not more than five in 10000 persons in the European Community, EC associated states and Canada.</li> <li>• <b>Research proposals must cover at least one of the following areas:</b> <ol style="list-style-type: none"> <li>1. Development of novel therapies in a preclinical setting (including small molecules, repurposing drugs, cell and gene advanced therapies) focusing on condition(s) with unmet medical needs</li> <li>2. Use of disease models suitable for medicinal product's development according to <a href="#">EMA guidelines</a></li> <li>3. Development of predictive and pharmacodynamics (PD) biomarkers (with appropriate analytical methods e.g. OMICS) in a preclinical setting (e.g. in the validated model or in pre-collected human samples) for monitoring the efficiency of the therapy. The model chosen must mimic the human diseases and be transposable so that the biomarker identified in animals can be valid for humans</li> <li>4. Proof of principle studies fostering an early (pre-clinical) stage of drug development (excluding interventional clinical trials of phase 1-4).</li> </ol> </li> <li>• <b>The following approaches and topics are excluded from the scope of the call:</b> <ol style="list-style-type: none"> <li>1. Therapeutic approaches concerning rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases</li> <li>2. Interventional clinical trials</li> <li>3. Surgery or radiation therapies</li> <li>4. Studies that focus on research to accelerate diagnosis or to set up new registry/cohort studies to explore disease progression and mechanisms as these were the focus of JTC 2019.</li> <li>5. Rare neurodegenerative diseases which are within the main focus of the <a href="#">Joint Programming Initiative on Neurodegenerative Disease Research (JPND)</a>. These are: Alzheimer's disease and other dementias; Parkinson's disease (PD) and PD-related disorders; Prion disease; Motor Neuron Diseases; Huntington's disease; Spinal Muscular Atrophy and dominant forms of Spinocerebellar Ataxia. Interested researchers should refer to the relevant JPND calls.  Childhood dementias/neurodegenerative diseases are not excluded.</li> </ol> </li> <li>• The research proposals must demonstrate complementary and synergistic interaction among the partner teams. There should be clear added value in the transnational collaboration over the individual projects.</li> <li>• The research projects must be based on novel ideas stemming from consolidated previous results or preliminary data and must be clearly endowed with benefit for the patients.</li> <li>• The consortia are encouraged to include early career scientists as principal investigators and partners from underrepresented countries (Czech Republic, Slovakia, Hungary, Lithuania, Poland and Turkey).</li> <li>• The project partners are expected to follow <a href="#">IRDiRC policies and guidelines</a>.</li> <li>• Consortium members of projects selected for funding must fix a common project start date, which will be the reference date for yearly and final reports and extensions.</li> <li>• Each partner need to respect the national/regional rules for funding.</li> <li>• The coordinator and respective partners must budget a sufficient amount for the expenses relate to the intermediate and the final status symposiums.</li> </ul>

	<ul style="list-style-type: none"> <li>The Call will be co-funded by the European Commission under the EJP-COFUND action.</li> </ul>
Proposal consists of	<p>Joint Pre-proposal application form:</p> <ul style="list-style-type: none"> <li>Partners contact details and affiliation</li> <li>Summary (max. 1 600 characters)</li> <li>Keywords and medicinal domain</li> <li>Name and affiliation of each partner</li> <li>Project description (max. 5 pages) – work plan, timeline, workflow</li> <li>CV of each partner with 5 relevant publications in the last 5 years (1 page each)</li> <li>Financial plan of each partner</li> </ul> <p>CZ: MEYS requested documentation:</p> <ul style="list-style-type: none"> <li>Eligible Costs Specification</li> <li>Statutory Declaration</li> </ul>
Evaluation criteria	<p>1) Excellence; 2) Impact; 3) Quality and efficiency of the implementation</p> <p>Max. score 15 points; overall threshold 12 points and individual criteria threshold 3 points;</p>
Research areas	All research areas and expertise relevant to the topic.
Call workshop	Not available
IOCB contact	<p>Please inform the IOCB Project Office about your intention to apply.</p> <p>Do not hesitate anytime to contact us for consulting, discussion or help.</p> <p>Veronika Palečková, <a href="mailto:veronika.paleckova@uochb.cas.cz">veronika.paleckova@uochb.cas.cz</a>, 420 220 183 266</p> <p>Jitka Šilerová, <a href="mailto:jitka.silerova@uochb.cas.cz">jitka.silerova@uochb.cas.cz</a>, +420 220 183 229</p>
Download documents	<p>EJPRD-JTC-2020_Summary</p> <p>EJPRD-JTC-2020_Call</p> <p>EJPRD-JTC-2020_Guidelines</p> <p>EJPRD-JTC-2020_Pre-Proposal Form</p> <p>EJPRD-JTC-2020_MEYS_Costs Specification</p>